Tokyo, Japan

Nobufusa Serizawa


Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 38(Granted Patents)


Location History:

  • Tokyo, JP (1994 - 2004)
  • late of Yokohama, JP (2004)
  • Yokohama, JP (2005)

Company Filing History:


Years Active: 1994-2005

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Nobufusa Serizawa

Introduction

Nobufusa Serizawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-Fas antibodies. With a total of 11 patents to his name, Serizawa's work has the potential to impact the treatment of various autoimmune diseases.

Latest Patents

Among his latest patents is the development of anti-Fas antibodies that are cross-reactive with both mouse and human Fas. These antibodies are useful in treating conditions related to abnormalities in the Fas/Fas ligand system. Another notable patent is a pharmaceutical composition containing an anti-human Fas antibody that induces apoptosis. This composition is designed for the prophylaxis and treatment of autoimmune diseases or rheumatoid arthritis. It allows for a reduced amount of anti-Fas antibody to be used, decreasing the likelihood of patients developing tolerance to the treatment.

Career Highlights

Throughout his career, Nobufusa Serizawa has worked with notable companies, including Sankyo Company, Limited and Sankto Company, Limited. His innovative work in the pharmaceutical industry has garnered attention and respect from his peers.

Collaborations

Some of his notable coworkers include Tohru Takahashi and Ryuta Koishi. Their collaborative efforts have contributed to the advancements in the field of immunology and pharmaceutical sciences.

Conclusion

Nobufusa Serizawa's contributions to the field of pharmaceuticals, particularly through his patents on anti-Fas antibodies, highlight his innovative spirit and dedication to improving medical treatments. His work continues to pave the way for advancements in the treatment of autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…